about
Cancer classification using the Immunoscore: a worldwide task forceBRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapiesTowards the introduction of the 'Immunoscore' in the classification of malignant tumoursBeyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesisA NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Convergence of nanotechnology and cancer prevention: are we there yet?Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancerPostoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy.Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury.Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.Impact of multimodal therapy in locally recurrent rectal cancerPhase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceAntitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinomaN-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration.Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma.Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancerPlatelets and cancer: a casual or causal relationship: revisited.Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic targetPhase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancerComparison of prognostic genomic predictors in colorectal cancer.Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancerHigh survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcomeSacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course.Long-term survival and recurrence outcomes following surgery for distal rectal cancer.The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancerRAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factorsIs resection of colorectal liver metastases after a second-line chemotherapy regimen justified?Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progressionExpanded RAS: refining the patient populationCancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypesCytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer.Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.
P50
Q21245495-1ED0330D-A517-465E-A0FD-D4CB9F0FE009Q26772276-20FADA0A-12B8-4F80-AA3E-390C18BB64A0Q27026489-AD3BCAA3-0F6B-4538-A277-9EE6A9EABCC9Q27026936-A8E48C17-A94F-4B59-977C-ACF29C5B2EC5Q27853184-D94F0845-C46F-48F6-ABF1-B40CD89832B5Q27853216-8E1BF438-2E92-4480-A9EC-90ECCEBE01CFQ28386699-714CC658-B288-437D-8AA8-7EECDA13E11AQ30489149-F1F5CAE6-CD36-4E14-A21A-5DEB84607DD7Q30744596-05CDF410-4ED9-4792-BFF1-2647F06A9E04Q33378977-B91892CE-66CC-4CF1-AF6A-424C0B36370DQ33386601-DC7F71BE-757A-4423-8535-82E65C0518F3Q33389221-7FFABBAE-0F58-4081-BD7E-94386716DBA6Q33609932-EF146C03-638E-4984-8F62-83E8D7779E72Q33627739-CC1A7108-17E1-4519-BB14-08A30AE1CD5AQ33709855-657B1E0F-4EC5-498E-979F-E3A53C92BAAFQ33721764-8C1C3748-10B9-4003-9CF3-3986CA90CBB0Q33813216-7C6213D9-CB32-4742-AC2C-146D63114800Q33889158-33248BC0-41D2-43EA-98A8-21CF5D1D0F10Q34203648-BCF47734-7B08-4CFE-AEE2-025493625766Q34249997-A6508861-47C1-49AD-9EAB-1A2885B4444EQ34294719-6A7E0869-8F75-49CF-B91F-D554D727926CQ34438536-A037111E-7233-445B-AB9B-DB31BCE7EED7Q34480200-FC2F7D37-837E-4EE6-92ED-AA20C054471CQ34603516-A3D23AD6-1337-4178-A467-D58932875C5BQ34628085-EBDB7139-805E-4752-A31A-7E3C4E7D8339Q34692073-F7A6879C-D063-45C1-802E-0B865EDC6E11Q34703562-E13577C3-9C01-40FA-885B-DBACD586DC95Q34743458-BF28AB00-71D8-4B6B-8607-D237FC2192C5Q34766307-A8DF2001-8CA8-4E76-8FDA-A3B885B11C7FQ34766318-9F77DD1B-04F8-488A-8A5B-8B6057471E18Q34966503-C0396C7A-F66F-4079-B516-6501FC0FD5A8Q35021680-AC02CD37-2F9C-4B81-B77D-9D9321DD5825Q35054390-99DDD1DD-7655-4358-96AA-6CBEDFB769FFQ35057318-B9229E65-624B-47EA-B6EE-3CD26E0419ACQ35082383-3614145B-0877-4F1A-9E9B-06B5C264E717Q35102335-A5B9D1FE-F548-4690-B63C-990F020648F8Q35102475-A83CA99B-B5A9-4F5C-A78C-3BEA719134C7Q35124790-76B6F8D9-ABB2-4A6E-BDC6-971E808C32FAQ35198371-BC9B5D80-C419-4D71-9B75-4E41E55745AFQ35218647-CE3F496E-AB7B-41FA-900E-61217C67D5EA
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Scott Kopetz
@ast
Scott Kopetz
@en
Scott Kopetz
@es
Scott Kopetz
@nl
Scott Kopetz
@sl
type
label
Scott Kopetz
@ast
Scott Kopetz
@en
Scott Kopetz
@es
Scott Kopetz
@nl
Scott Kopetz
@sl
altLabel
ES Kopetz
@en
prefLabel
Scott Kopetz
@ast
Scott Kopetz
@en
Scott Kopetz
@es
Scott Kopetz
@nl
Scott Kopetz
@sl
P106
P1153
22634969100
P21
P31
P496
0000-0001-9647-3416